Chai S, Zhang R, Zhang Y, Carr RD, Zheng Y, Rajpathak S, Ji L (2022)
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
Front Endocrinol (Lausanne) 13: 994944

Berger JP, SinhaRoy R, Pocai A, Kelly TM, Scapin G, Gao YD, Pryor KAD, Wu JK, Eiermann GJ, Xu SS, Zhang X, Tatosian DA, Weber AE, Thornberry NA, Carr RD (2018)
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
Endocrinol Diabetes Metab 1: e00002

Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, Deacon CF, Ahren B (2010)
Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men
J Clinical Endocrinology Metab 95: 872

Deacon CF, Carr RD, Holst JJ (2008)
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Front Biosci 13: 1780

Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsboll T (2006)
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
European Journal of Endocrinology 155: 485

Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005)
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
Diabetologia 48: 1882